Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis

Neuro-Oncology

Volumn 17, Issue 1, 2015, Pages 63-69

  Danielsen, Stine A ^a,b,c   Lind, Guro E ^a,b,c   Kolberg, Matthias ^a,b   Høland, Maren ^a,b   Bjerkehagen, Bodil ^a   Hall, Kirsten Sundby ^a   Van Den Berg, Eva ^d   Mertens, Fredrik ^e   Smeland, Sigbjørn ^a,b   Picci, Piero ^f   Lothe, Ragnhild A ^a,b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Methylation; MPNST; NF1; RASSF1A; Survival

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHILD; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DNA METHYLATION; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; POLYMERASE CHAIN REACTION; PROMOTER REGION; QUANTITATIVE ANALYSIS; RISK FACTOR; COMPLICATION; FEMALE; GENETICS; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; NEURILEMOMA; NEUROFIBROMATOSIS TYPE 1; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; DNA METHYLATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEURILEMMOMA; NEUROFIBROMATOSIS 1; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84922572928     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou140     Document Type: Article

References (50)

1. Carroll SL. Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol. 2012;123(3): 321-348.
2. Evans DG, Huson SM, Birch JM. Malignant peripheral nerve sheath tumours in inherited disease. Clin Sarcoma Res. 2012;2(1):17-12.
3. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107(5): 1065-1074.
4. Kolberg M, Holand M, Agesen TH, et al. Survival meta-analyses for .1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol. 2013;15(2): 135-147.
5. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249(6):1014-1022.
6. Skotheim RI, Kallioniemi A, Bjerkhagen B, et al. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol. 2003;21(24): 4586-4591.
7. Brekke HR, Kolberg M, Skotheim RI, et al. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro-oncol. 2009;11:514-528.
8. Brekke HR, Ribeiro FR, Kolberg M, et al. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol. 2010;28(9):1573-1582.
9. Torres KE, Zhu QS, Bill K, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011;17(12): 3943-3955.
10. Upadhyaya M, Spurlock G, Thomas L, et al. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis. Hum Mutat. 2012;33(4):763-776.
11. Rahrmann EP, Watson AL, Keng VW, et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet. 2013; 45(7):756-766.
12. Aagesen TH, Florenes VA, Molenaar WM, et al. Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol. 2005;64(1):74-81.
13. Berner JM, Sorlie T, Mertens F, et al. Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway. Genes Chromosomes Cancer. 1999;26(2):151-160.
14. Kourea HP, Cordon-Cardo C, Dudas M, et al. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol. 1999;155(6):1885-1891.
15. Nielsen GP, Stemmer-Rachamimov AO, Ino Y, et al. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 1999; 155(6):1879-1884.
16. Perrone F, Da RL, Orsenigo M, et al. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. Neuro Oncol. 2009;11(6):725-736.
17. Holtkamp N, Malzer E, Zietsch J, et al. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol. 2008;10(6):946-957.
18. Holtkamp N, Okuducu AF, Mucha J, et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis. 2006; 27(3):664-671.
19. Upadhyaya M, Kluwe L, Spurlock G, et al. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat. 2008; 29(1):74-82.
20. Bottillo I, Ahlquist T, Brekke H, et al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol. 2008;217(5):693-701.
21. Sun D, Tainsky MA, Haddad R. Oncogene mutation survey in MPNST cell lines enhances the dominant role of hyperactive Ras in NF1 associated pro-survival and malignancy. Transl Oncogenomics. 2012;5:1-7; doi:10.4137/TOG.S8830.
22. Donninger H, Barnoud T, Nelson N, et al. RASSF1A and the rs2073498 cancer associated SNP. Front Oncol. 2011;1(54): 11-17.
23. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65(9):3497-3508.
24. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci. 2007;120(18):3163-3172.
25. Kawaguchi KI, Oda Y, Saito T, et al. DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol. 2006;19(1): 106-114.
26. Feber A, Wilson GA, Zhang L, et al. Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Res. 2011;21(4):515-524.
27. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta. 2009;1796(2):114-128.
28. Lind GE, Kleivi K, Meling GI, et al. ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol. 2006;28(5-6):259-272.
29. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res. 2001;29(13):e65.
30. Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques. 2002;33(3):632-649.
31. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. PNAS. 1996;93(18):9821-9826.
32. Lind GE, Raiborg C, Danielsen SA, et al. SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis. Oncogene. 2011;30(37):3967-3978.
33. Weisenberger DJ, Campan M, Long TI, et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 2005; 33(21):6823-6836.
34. Pfeifer GP, Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc). 2005;70(5): 576-583.
35. Vos MD, Martinez A, Elam C, et al. A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res. 2004;64(12):4244-4250.
36. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta. 2007;1776(1):58-85.
37. Honda S, Haruta M, Sugawara W, et al. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer. 2008; 123(5):1117-1125.
38. Maat W, van der Velden PA, Out-Luiting C, et al. Epigenetic inactivation of RASSF1a in uveal melanoma. Invest Ophthalmol Vis Sci. 2007;48(2):486-490.
39. Martins AT, Monteiro P, Ramalho-Carvalho J, et al. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res Treat. 2011;129(1):1-9.
40. Wang J, Wang B, Chen X, et al. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis. 2011; 32(3):411-416.
41. Seidel C, Bartel F, Rastetter M, et al. Alterations of cancerrelated genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer. 2005; 114(3):442-447.
42. Tomizawa Y, Kohno T, Kondo H, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res. 2002;8(7): 2362-2368.
43. Kawai Y, Sakano S, Suehiro Y, et al. Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma. Ann Oncol. 2010;21(8): 1612-1617.
44. Gonzalez-Gomez P, Bella MJ, Arjona D, et al. Aberrant CpG island methylation in neurofibromas and neurofibrosarcomas. Oncol Rep. 2003;10(5):1519-1523.
45. Harder A, Rosche M, Reuss DE, et al. Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours. Eur J Cancer. 2004;40(18): 2820-2828.
46. Luijten M, Redeker S, van Noesel MM, et al. Microsatellite instability and promoter methylation as possible causes of NF1 gene inactivation in neurofibromas. Eur J Hum Genet. 2000;8(12): 939-945.
47. Fishbein L, Eady B, Sanek N, et al. Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells. Cancer Genet Cytogenet. 2005;157(2): 181-186.
48. Bradtmo ller M, Hartmann C, Zietsch J, et al. Impaired PTEN expression in human malignant peripheral nerve sheath tumours. PLoS ONE. 2012;7(11):e47595.
49. Perrone F, Tabano S, Colombo F, et al. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res. 2003;9(11):4132-4138.
50. Endo M, Kobayashi C, Setsu N, et al. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011;17(11): 3771-3782.